10X Genomics (TXG) Stock
Key stats
- Market cap
- $7.56B
- Price / Earnings ratio
- -117.1x
- EPS (TTM)
- -$0.59
- Volume
- Loading
- 52-week high
- $102.81
- 52-week low
- $12.80
- EPS vs analyst estimate
- -46.7%Q3 FY25 · -$0.22 vs -$0.15
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with TXG
Recent news

3 Promising Genomics Stocks to Add to Your Portfolio Now
3 Promising Genomics Stocks to Add to Your Portfolio Now
TXG

Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged
Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged
TXG

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
TXG

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
TXG
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.39
- MACD 12/26/9
- -2.83
- EMA 9 of MACD
- -1.13
- MACD histogram
- -1.71
- SMA 50
- $74.06
- Price below SMA 50
- EMA 50
- $70.47
- Price below EMA 50
- SMA 200
- $41.40
- Price above SMA 200
- EMA 200
- $45.84
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.22 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

3 Promising Genomics Stocks to Add to Your Portfolio Now
3 Promising Genomics Stocks to Add to Your Portfolio Now
TXG

Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged
Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged
TXG

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
TXG

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
TXG

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
TXG

Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
TXG

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG

3 Analysts, 3 Trades to Make Today
3 Analysts, 3 Trades to Make Today
TXG

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
TXG
News tone: automated (AI) classification of the article's content, not a price prediction.
About 10X Genomics
We are a life science technology company building products to interrogate, understand and master biology. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Serge Saxonov Ph.D. | Co-Founder, CEO & Director | 1977 |
| Mr. Adam S. Taich | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | 1975 |
| Dr. Benjamin J. Hindson Ph.D. | Co-Founder, President, Chief Scientific Officer & Director | 1975 |
| Mr. Jim Goodrich | Chief of Global Operations | — |
| Mr. Michael Schnall-Levin Ph.D. | Founding Scientist & CTO | — |
| Ms. Cassie Corneau | Manager of Investor Relations & Strategic Finance | — |
| Dr. Randy Wu | General Counsel and Secretary | — |
| Ms. Mennah Moustafa | Chief Commercial Officer | — |
| Mr. Jens Durruthy | Associate Director of Product Management | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 37.39
- MACD 12/26/9
- -2.83
- EMA 9 of MACD
- -1.13
- MACD histogram
- -1.71
- SMA 50
- $74.06
- Price below SMA 50
- EMA 50
- $70.47
- Price below EMA 50
- SMA 200
- $41.40
- Price above SMA 200
- EMA 200
- $45.84
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $50.00
- Average
- $81.30
- High
- $110.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.4 | +3.2 | ||||||||||
| 2022 | -34.0 | -18.1 | -6.0 | -41.1 | +0.7 | -1.9 | -14.3 | -17.2 | -11.7 | -4.1 | +37.0 | -7.9 |
| 2023 | +32.6 | -0.1 | +19.6 | -2.3 | +0.1 | +5.0 | +11.0 | -16.7 | -23.7 | -12.9 | +26.8 | +22.3 |
| 2024 | -23.3 | +7.0 | -17.6 | -21.0 | -16.7 | -12.3 | +11.2 | +18.6 | -2.0 | -24.8 | -2.6 | -12.8 |
| 2025 | +5.7 | -26.0 | -11.4 | -4.6 | +17.7 | +22.5 | +11.5 | +7.1 | -12.6 | +10.1 | +37.3 | -9.8 |
| 2026 | +21.5 | +15.5 | -8.3 | +0.0 | +26.2 | +29.6 | +21.0 | +32.8 | +50.7 | -21.0 | -5.8 |



